The ORBITA trial: A point of view

VITOR DORNELA DE OLIVEIRA¹, FERNANDO RABIOLGIO GIUGNI¹, EDUARDO BELLO MARTINS², DIOGO FREITAS CARDOSO DE AZEVEDO²,
EDUARDO GOMES LIMA²*, 8, CARLOS VICENTE SERRANO JÚNIOR²

¹Cardiology Resident Physician, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
²Department of Atherosclerosis, Instituto do Coração do Hospital das Clínicas da FMUSP (InCor-HC-FMUSP), São Paulo, SP, Brazil

SUMMARY

Treatment of stable coronary artery disease (CAD) relies on improved prognosis and relief of symptoms. National and international guidelines on CAD support the indication for revascularization in patients with limiting symptoms and refractory to drug treatment. Previous studies attested the efficacy of angioplasty to improve angina as well as the functional capacity of patients with symptomatic stable CAD. The ORBITA trial, recently published in an international journal, showed no benefit in terms of exercise tolerance compared to a placebo procedure in a population of single-vessel patients undergoing contemporary percutaneous coronary intervention. In this point of view article, the authors discuss the ORBITA trial regarding methodological issues, limitations and clinical applicability.

Keywords: Coronary Artery Disease. Percutaneous Coronary Intervention. Stents. Stable Angina.
clinical optimization, with titration of anti-anginal medications by telephone consultations. After this time interval, 200 patients remained symptomatic and were included for analysis of the results. They all underwent coronary angiograms, with randomization performed during the procedure. A total of 105 subjects were randomized to angioplasty and the remaining 95 were maintained in the placebo group.

Measurements of fractional flow reserve (FFR) and immediate wave-free ratio (IFR) were taken from all patients. All angioplasty procedures were performed using second-generation drug-eluting stents. The median angiographic epicardial stenosis among study participants was 85.7% (77.4-93.0). Median FFR, in turn, was 0.72 (0.57-0.81). Fifty-seven (57) patients (29%) had an FFR value greater than 0.80, and 64 of them (32%) had IFR greater than 0.89. We must keep in mind that FFR > 0.82 or iFR > 0.92 was found in 25% of patients in the PCI group, which indicates lesions with no functional impairment and no formal recommendation for revascularization. After PCI, there was improvement in the median values of FFR and IFR (0.90 and 0.94, respectively). A total of four patients in the placebo group (4.2%) required angioplasty due to complications associated with the coronary angiogram.

Study blinding was very well done, which was a merit of the researchers. The exams (exercise test, echocardiogram and catheterization) were performed by professionals who were not part of the research group. Neither patients nor researchers knew the group to which each individual belonged. During catheterization, patients were sedated and remained with headphones throughout the procedure. This fact ensures that the placebo effect has in fact been eliminated from the analysis of the results.

Patients were followed for six weeks after the procedure (angioplasty or placebo). The exams and questionnaires analyzed in the outcomes were performed before the catheterization procedure and after the follow-up period. There was no statistically significant difference in any of the outcomes analyzed, except for echocardiography with pharmacological stress, favoring angioplasty (p=0.0011).

Although it was a very well-designed study, with enviable methodology and blinding, some criticism should be considered. First, this was a low-risk population (single-vessel disease, without ventricular dysfunction), which prevents the extrapolation of study results to the other spectra of the disease. It is also important to note that patients were poorly symptomatic with CCS I-II angina in most cases, and that approximately one-third of the patients did not even have a functionally significant obstruction based on FFR and IFR measures. In addition, the DEFER (Deferral Versus Performance of PTCA [percutaneous transluminal coronary angioplasty] in Patients Without Documented Ischemia) trial, a prospective and randomized study, clearly demonstrated that the long-term prognosis of patients with FFR > 0.75 and intermediate lesions not treated with angioplasty is excellent (risk of cardiac death or myocardial infarction < 1%).

It is noteworthy that the follow-up time in the ORBITA trial was short, and difficulties regarding drug adherence in the long-term could be considered. Once in this trial there was an average of approximately three anti-anginal drugs, a longer follow-up time would be necessary for a better comparison between treatment strategies.

It is a fact that the ORBITA is not the first study to reveal the ineffectiveness of angioplasty in promoting symptomatic improvement or improvement of exercise tolerance in specific subpopulations in the context of stable CAD. A subanalysis of the BARI-2D trial evaluated the health status and symptoms of patients randomized to revascularization or drug treatment.

In the study, patients treated with surgical revascularization showed improvement of symptoms, which did not occur among those who underwent angioplasty in a long-term follow-up. Another clinical trial conducted by Hambrecht et al. compared ICP with physical rehabilitation and showed better tolerance to exercise in the group treated with physical rehabilitation alone.

Finally, a meta-analysis published in 2013 including a total of 4,064 patients with objective documentation of ischemia failed to demonstrate improved angina among patients undergoing PCI compared with those on drug therapy.

While evaluating the body of available evidence, it must be kept in mind that angina is a symptom with complex and multifactorial pathophysiology, so the reduction of coronary flow caused by stenosis in the epicardial artery is not the only factor involved with the pain (Figure 1). The regulation of this flow also depends on the preservation of endothelial function and microvasculature. Furthermore, nonvascular factors such as myocardial hypertrophy can compromise blood flow to a given territory. Angina is often a difficult symptom to characterize, being greatly influenced by subjective factors. Also, thoracic pain of diverse etiologies may occur concomitantly, reducing the beneficial effect of revascularization.

A possible conclusion is that the ORBITA trial was daring to test the concept of the placebo effect of PCI; however, we must be careful about its results. PCI adequately fulfilled its role of resolving epicardial vessel obstruction, which is clear with improved FFR/IFR values.
Oliveira et al. reV assoc Med Bras 2018; 64(2):100-103

and stress echocardiography. Nevertheless, revascularization of the epicardial artery did not necessarily translate into an improvement in angina, much less a better tolerance to exercise, which is understandable given the multifactorial nature of these variables.

Much is debated whether the ORBITA trial will impact the guidelines for management of stable CAD. Considering the limitations mentioned, as well as the profile of patients included in the ORBITA, we believe that little will change in clinical practice, since the current guidelines would not even suggest revascularization for many patients included in the study. In any case, the study leads the medical community to reflect on the indication of intervention in the population with chronic CAD, always pondering the real benefits, risks and expectations of both the patient and the physician indicating the procedure. Understanding the pathophysiology of the disease and adequately interpreting the clinical evidence are fundamental steps in this process.

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

**RESUMO**

Estudo ORBITA: um ponto de vista

O tratamento da doença arterial coronariana (DAC) estável se baseia na melhora do prognóstico e alívio de sintomas. Diretrizes nacionais e internacionais sobre a DAC respaldam a indicação de revascularização em pacientes com sintomas limitantes e refratários ao tratamento medicamentoso. Estudos prévios atestavam a eficácia da angioplastia na melhora da angina, bem como na capacidade funcional de pacientes com DAC estável sintomática. O estudo ORBITA, publicado recentemente em revista internacional, mostrou em população de uniarteriais submetidos a angioplastia com stent farmacológico ausência de benefício na tolerância ao exercício quando comparado a procedimento placebo. No presente ponto de vista, os autores discutem o trabalho em questão quanto a método, limitações e aplicabilidade clínica.


**REFERENCES**


